Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.605 AUD | -0.82% | -4.62% | +15.89% |
May. 15 | Recce Pharmaceuticals Doses First Patient in Urosepsis Rapid Infusion Clinical Trial | MT |
May. 10 | Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.89% | 83.75M | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- RCE Stock
- News Recce Pharmaceuticals Ltd
- Recce Makes Headway On Human Trials of Anti-Infective